4 - Rain Oncology Inc. (0001724979) (Issuer)

– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve

NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca

– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p

– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Required number of progression events achieved in the Phase 3 pivotal MANTRA trial to trigger the primary analysis of progression free survival (PFS) in patients with dedifferentiated liposarcoma (DDLPS) – – Topline data for the MANTRA trial expected this quarter – – Phase 2 MANTRA-2 trial continues to enroll across MDM2-amplified advanced solid tumor types – – Phase 1/2 MANTRA-4 trial in advanced solid tumors exhibiting loss of the

NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the first quarter ended March 31, 2023 and highlights of recent progress on Thursday, May 11, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: May 11, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers

– Year-end cash position of $130.5 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Topline data for Phase 3 pivotal MANTRA trial expected in second quarter of 2023 – – Phase 2 MANTRA-2 trial continues to enroll – – Phase 1/2 MANTRA-4 trial anticipated to commence in mid-2023 – – Management to host conference call and webcast today at 5:00 PM Eastern Time – NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage biotechnology company developing precision oncology t

NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 and highlights of recent progress on Thursday, March 9, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: March 9, 2023Time: 2:00 PT (5:00 p

– End of third quarter cash position of $90.7 million excludes the recent $50 million registered offering, and together, provide a cash runway into 2025 – – Phase 3 pivotal MANTRA trial topline data now anticipated in first quarter of 2023 – – Phase 2 MANTRA-2 trial preliminary interim data demonstrates encouraging monotherapy signal in ten evaluable patients; MANTRA-2 continues to enroll – – Phase 2 MANTRA-3 trial deprioritized to rationalize use of financial resources – – Phase 1/2 MANTRA-4 trial anticipated to commence in first quarter 2023 – – Management to host conference call and webcast today at 5:00 PM Eastern Time – NEWARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Rain Ther

NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: November 10, 2022Time: 2:00 PT (5:00 pm ET)D

– Quarter-end cash position of $105.7 million provides ample cash runway into mid-2024 – – Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance; topline data anticipated in first half of 2023 – – Phase 2 MANTRA-2 trial ongoing as planned with interim data anticipated in fourth quarter 2022 – – Management to host conference call and webcast today at 5:00 PM Eastern Time – NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) --  Rain Therapeutics Inc. (NASDAQ:RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactiva

SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13G/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)

SC 13G - Rain Oncology Inc. (0001724979) (Subject)

SC 13D/A - Rain Oncology Inc. (0001724979) (Subject)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

4 - Rain Oncology Inc. (0001724979) (Issuer)

Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. ("Pathos") today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. ("Merger Sub"), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (NASDAQ:RAIN) ("Rain") for $1.16 per share in cash plus one contingent value right per share (each, a "CVR"), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated as of January 26, 2024, by and among Pathos, Merger Sub, Equiniti Trust Company, LLC, and Forti

NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) ("Rain"), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. ("Pathos") will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a "CVR") for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions contemplated by the Merger Agreement (collectively, the "Transaction"). The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023. The Rain Board reached this determinati

NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on the Company's key developments and business operations. "Rain continues to evaluate a number of strategic opportunities to add value for its stockholders," said Avanish Vellanki, co-founder and chief executive officer of Rain. "We anticipate being able to provide a public update on our efforts before the end of the year." Third Quarter 2023 Financial Highlights For the three and nine months ended September 30, 2023, Rain reported a net loss of $7.0 million and $49.6 million, respect

NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NASDAQ:RAIN) ("Rain") confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right ("CVR") representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain's programs. Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are committed to acting in the best interests of all stockholders. Consistent with its fiduciary duties, Rain's Board of Directors, i

– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve

NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca

– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma (DD LPS) are ongoing with data and findings to be presented at a medical conference in 4Q23 – – Company continuing to evaluate opportunities for expansion of its pipeline across precision oncology strategies – – Overall workforce reduction of approximately 65% of the Company's employees; with a transition of Chief Medical Officer (CMO) responsibilities – – Year-end 2023 cash guidance of $75-80mm, with cash runway to year-e

– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p

– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Required number of progression events achieved in the Phase 3 pivotal MANTRA trial to trigger the primary analysis of progression free survival (PFS) in patients with dedifferentiated liposarcoma (DDLPS) – – Topline data for the MANTRA trial expected this quarter – – Phase 2 MANTRA-2 trial continues to enroll across MDM2-amplified advanced solid tumor types – – Phase 1/2 MANTRA-4 trial in advanced solid tumors exhibiting loss of the

NEWARK, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the first quarter ended March 31, 2023 and highlights of recent progress on Thursday, May 11, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: May 11, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers

-SEC 8K Filing

Rain Oncology Inc (NASDAQ:RAIN) has agreed to be acquired by Pathos AI Inc. for $1.16 in cash per share plus a non-tradeable contingent value right (CVR) for potential cash payments of up to approximately $0.17 per share. The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023.  "After a thorough assessment, the Rain Board determined that this Transaction is in the best interests of our stockholders, as it leverages Rain's strong cash position to provide a confirmed cash takeout for our stockholders and retains some future potential upside due to Pathos' continued interest in further developing milademetan for cancer patients using

Pursuant and subject to the terms of the merger agreement, a subsidiary of Pathos will commence a tender offer to acquire all outstanding shares of Rain for $1.16 in cash per share plus a CVR representing a contractual right to receive two potential contingent aggregate cash payments as follows: Cash CVR Payment: an aggregate amount equal to $5.0 million (up to approximately $0.14 per share), minus (A) certain expenses incurred related to pending or future litigation involving Rain and its directors or officers, minus (B) any shortfall in a target level of net cash, plus (C) any cash at closing in excess of the target net cash. Development CVR Payment: either (i) $1.0 million (approximat

Rain Oncology (NASDAQ:RAIN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 72.06 percent increase over losses of $(0.68) per share from the same period last year.

The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Parks! America The Trade: Parks! America, Inc. (OTC:PRKA) Director Charles Kohnen acquired a total of 100,000 shares an average price of $0.40. To acquire these shares, it cost around $40,000. What’s Happening: Total revenues for the fiscal quarter ended July 2,

Rain Oncology, Inc. (NASDAQ:RAIN) ("Rain") confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right ("CVR") representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain's programs. Rain's Board of Directors and management team regularly review opportunities to generate stockholder value and are committed to acting in the best interests of all stockholders.Consistent with its fiduciary duties, Rain's Board of Directors, in consultation with its independent financial and legal

Gainers Bellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 1394.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 million. Cingulate (NASDAQ:CING) stock increased by 12.59% to $0.58. The company's market cap stands at $10.0 million. Rain Oncology (NASDAQ:RAIN) stock rose 11.11% to $1.1. Rain Oncology's trading volume hit 98.3K shares by close, accounting for 45.0% of its average volume over the last 100 days. The company's market cap stands at $40.0 million. Artelo Biosciences (NASDAQ:ARTL) shares rose 9.72%

  On Tuesday, 647 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: Bank of America (NYSE:BAC) was the biggest company on a market cap basis to set a new 52-week low. Blue Star Foods (NASDAQ:BSFC) was the smallest company by market cap to set a new 52-week low. Stryve Foods (NASDAQ:SNAX) shares dropped the most, trading down 27.96% to reach its new 52-week low. Royal Bank of Canada (NYSE:RY) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low. Stocks dropping to new 52-week lows on Tuesday: Bank of America (NYSE:BAC) shares set a new yearly low of $26.16 this morning. The stock was down 0.75% on

Citigroup analyst Yigal Nochomovitz maintains Rain Oncology (NASDAQ:RAIN) with a Neutral and lowers the price target from $1.5 to $1.

  Monday's session saw 175 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Pfizer (NYSE:PFE). The smallest company by market cap to set a new 52-week low was Kiromic BioPharma (NASDAQ:KRBP). Tenon Medical (NASDAQ:TNON) made the largest move down on the session, with shares plummeting 38.98% to reach its 52-week low. Revance Therapeutics (NASDAQ:RVNC) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. Stocks that set new 52-week lows on Monday are as follows: Pfizer (NYSE:PFE) shares moved down 1.71% on Monday to hit a new 52-week low of $33.54, drif